

TABLE 1. Emicizumab efficiency monitored by TGA (ETP and Peak)

Emicizumab initiation phase		PRP at basal	PRP			Normal PRP 40 healthy volunteers (Men from 18-43 y.o.) (5-95 percent)
			1 week post Emicizumab	3 weeks post Emicizumab	4 weeks post Emicizumab	
Case n°1	ETP (nM*min)	479	455	793	1041	1041-1574
	Peak (nM)	15	12.9	25.1	50.1	68-150
Case n°2	ETP (nM*min)	382	809	950	844	1041-1574
	Peak (nM)	14.5	26.1	36.6	35.6	68-150

†. Case n°1: TGA on PRP at basal (4 days after stopping FEIBA®). TGA just before emicizumab. TG residual rates (7 days after 3 mg/kg of emicizumab)

‡. Case n°2: TGA on PRP at basal (3 days after stopping Octanate®). TGA just before emicizumab. TG residual rates (7 days after 3 mg/kg emicizumab injection).